{"filing":{"accession_number":"0001193125-26-265830","cik":"0001980845","ticker":"ENGNW","company_name":"enGene Therapeutics Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"engn-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312526265830/engn-20260609.htm"},"events":[{"id":5650,"run_id":4953,"accession_number":"0001193125-26-265830","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from enGene Therapeutics' 2026 Annual General Meeting held on June 9, 2026. The filing reports final voting tallies for Proposal 1 (Election of Directors) and Proposal 2 (Appointment and Remuneration of Auditor), with detailed vote counts for each director nominee and the auditor appointment. This is a quintessential Item 5.07 disclosure required by SEC rules and is material to investors as it confirms board composition and auditor selection.","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5843,"accession_number":"0001193125-26-265830","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from enGene Therapeutics' 2026 Annual General Meeting held on June 9, 2026. The filing reports final voting tallies for Proposal 1 (Election of Directors) and Proposal 2 (Appointment and Remuneration of Auditor), with detailed vote counts for each director nominee and the auditor appointment. This is a quintessential Item 5.07 disclosure required by SEC rules and is material to investors as it confirms board composition and auditor selection.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:12:06.425736+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5843,"accession_number":"0001193125-26-265830","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from enGene Therapeutics' 2026 Annual General Meeting held on June 9, 2026. The filing reports final voting tallies for Proposal 1 (Election of Directors) and Proposal 2 (Appointment and Remuneration of Auditor), with detailed vote counts for each director nominee and the auditor appointment. This is a quintessential Item 5.07 disclosure required by SEC rules and is material to investors as it confirms board composition and auditor selection.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:12:06.425736+00:00","company_name":"enGene Therapeutics Inc.","ticker":"ENGNW","filing_date":"2026-06-10"}]}